首页> 外文OA文献 >SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

【2h】

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

机译：SAKK 24/09：贝伐单抗联合紫杉醇与贝伐单抗联合节律性环磷酰胺和卡培他滨作为HER2阴性晚期乳腺癌患者的一线治疗的安全性和耐受性-多中心随机III期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial [J] . Christoph Rochlitz, Martin Bigler, Roger von Moos, BMC Cancer . 2016,第1期

机译：SAKK 24/09：贝伐单抗联合紫杉醇与贝伐单抗联合节律性环磷酰胺和卡培他滨作为HER2阴性晚期乳腺癌患者的一线治疗的安全性和耐受性-多中心随机III期研究
2. A randomized, multicenter, phase II study evaluating the efficacy of interventional maintenance endocrine therapy with bevacizumab following fixed cycles of bevacizumab plus paclitaxel in advanced/metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 BOOSTER trial [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：随机，多中心，II期研究评估介入维持内分泌治疗与贝伐单抗后的贝伐单抗加紫杉醇在晚期/转移性ER阳性HER2阴性乳腺癌中的培养基中的疗效：JBCRG-M04增强试验
3. 5058 Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial [J] . I.Lang, M.Inbar, G.Steger, European Journal of Cancer Supplements . 2009,第2期

机译：5058贝伐单抗（Bev）联合卡培他滨（X）或每周紫杉醇（Pac）作为HER2阴性的局部复发或转移性乳腺癌（LR / MBC）的一线治疗：CECOG III期TURANDOT试验
4. Effects of laser immunotherapy on late-stage, metastatic breast cancer patients in a Phase Ⅱ clinical trial [C] . Gabriela L. Ferrel, Feifan Zhou, Xiaosong Li, Biophotonics and immune responses IX . 2014

机译：Ⅱ期临床试验中激光免疫疗法对晚期转移性乳腺癌患者的影响
5. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter randomized phase III trial [O] . Christoph Rochlitz, Martin Bigler, Roger von Moos, 2016

机译：SAKK 24/09：贝伐单抗联合紫杉醇与贝伐单抗联合节律性环磷酰胺和卡培他滨作为HER2阴性晚期乳腺癌患者的一线治疗的安全性和耐受性-多中心随机III期研究
6. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. [O] . Rochlitz, C., Bigler, M., von Moos, R., 2016

机译：SAKK 24/09：贝伐单抗联合紫杉醇与贝伐单抗联合节律性环磷酰胺和卡培他滨作为HER2阴性晚期乳腺癌患者的一线治疗的安全性和耐受性-多中心，随机，III期试验。

SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

著录项

引文网络

相似文献

相关主题

期刊订阅